Recent News

• 05.18.2025 - Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
• 05.18.2025 - Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
• 05.18.2025 - Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
• 05.13.2025 - Applied Therapeutics Reports First Quarter 2025 Financial Results
• 05.13.2025 - Applied Therapeutics Reports First Quarter 2025 Financial Results
• 05.13.2025 - Applied Therapeutics Reports First Quarter 2025 Financial Results
• 05.09.2025 - Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
• 05.09.2025 - Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
• 05.09.2025 - Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1
• 05.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.30.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2025 - ARS Annual Report to Security Holders